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Abstract 
 Context. Cancer patients experience a broad range of physical and psychological 
symptoms as a result of their disease and its treatment. On average, these patients report ten 
unrelieved and co-occurring symptoms. 
 Objectives. To determine if subgroups of oncology outpatients receiving active treatment 
(n=582) could be identified based on their distinct experience with thirteen commonly occurring 
symptoms; to determine whether these subgroups differed on select demographic, and clinical 
characteristics; and to determine if these subgroups differed on quality of life (QOL) outcomes. 
 Methods. Demographic, clinical, and symptom data from one Australian and two U.S. 
studies were combined. Latent class analysis (LCA) was used to identify patient subgroups with 
distinct symptom experiences based on self-report data on symptom occurrence using the 
Memorial Symptom Assessment Scale (MSAS). 
 Results. Four distinct latent classes were identified (i.e., All Low (28.0%), Moderate 
Physical and Lower Psych (26.3%), Moderate Physical and Higher Psych (25.4%), All High 
(20.3%)). Age, gender, education, cancer diagnosis, and presence of metastatic disease 
differentiated among the latent classes. Patients in the All High class had the worst QOL scores. 
 Conclusion. Findings from this study confirm the large amount of interindividual 
variability in the symptom experience of oncology patients. The identification of demographic 
and clinical characteristics that place patients are risk for a higher symptom burden can be used 
to guide more aggressive and individualized symptom management interventions. 
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Introduction 
  Cancer patients experience a broad range of physical and psychological symptoms as a 
result of their disease and its treatment. On average, patients report ten unrelieved and co-
occurring symptoms.1 However, clinical experience and emerging evidence2-7 suggest that a 
large amount of inter-individual variability exists in patients’ symptom experiences. 
  To develop a better understanding of this inter-individual variability, we conducted a 
number of studies using cluster analysis2,6 or latent class analysis (LCA)4,5 to identify subgroups 
of oncology patients based on their severity ratings for four common symptoms (fatigue, pain, 
sleep disturbance, depression). In the first two studies done in the U.S.6 and Israel,2 four distinct 
subgroups of oncology patients were identified using hierarchical cluster analysis. Of note, 
approximately 15% of these patients reported high levels (i.e., All High subgroup) and 35% 
reported low levels (i.e., All Low subgroup) of all four symptoms. In both of these studies, 
compared to the All Low subgroup, patients in the All High subgroup were significantly younger 
and less likely to be married or partnered. In addition, the All High subgroup reported poorer 
functional status and lower quality of life (QOL) scores.  
  In two of our recent studies, LCA was used to identify subgroups of oncology patients 
and their family caregivers5 or subgroups of patients with breast cancer4 based on their severity 
ratings for the same four symptoms. In these two studies, three distinct subgroups were 
identified, with between 7%4 and 12%5 of the participants being classified in the All High 
subgroup. Consistent with our previous reports,2,6 compared to the All Low subgroup, 
participants in the All High subgroup were significantly younger and had a lower functional 
status.  
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  In another group of studies that used symptom occurrence ratings from the Memorial 
Symptom Assessment Scale (MSAS)8 or symptom severity ratings from the European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 
(EORTC QLQ-C30)9 to identify patients with a higher symptom burden, two10-12 or three7,13 
subgroups were identified. In all five studies,7,10-13 All Low and All High symptom subgroups 
were identified. Although the demographic and clinical characteristics that were associated with 
a higher symptom burden were not consistent across these five studies, patients in the All High 
subgroup reported statistically significant and clinically meaningful decrements in functional 
status and QOL. The reasons for these inconsistent findings on number of subgroups identified, 
as well as the predictors of symptom subgroup membership,10-13 may relate to differences in: 
sample sizes; the demographic and clinical characteristics of the participants; the number of 
symptoms evaluated; the dimension of the symptom experience used to create the subgroups; 
and the statistical procedures employed.  
  Given the high prevalence of co-occurring symptoms and the large amount of inter-
individual variability in oncology patients’ symptom experiences, findings from the studies cited 
above suggest that the identification of subgroups of patients with a higher symptom burden may 
assist clinicians to provide more aggressive and individualized symptom management. Given this 
promising, albeit limited amount of research, the purposes of this study were to determine if 
subgroups of oncology outpatients receiving active treatment (n=582) could be identified based 
on their distinct experience with thirteen common symptoms; to determine whether these 
subgroups differed on select demographic and clinical characteristics; and to determine if these 
subgroups differed on QOL outcomes. 
Methods 
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Study Samples 
  Demographic, clinical, and symptom data from one Australian study (i.e., Symptom 
Clusters Study) and two U.S. studies (i.e., Fatigue, Pain, and Sleep Study (FPS Study), Symptom 
Prevalence Study) were combined to conduct this analysis. All three studies enrolled patients 
who were receiving active treatment for their cancer. Detailed information on recruitment 
procedures, study methods, and sample characteristics for these studies is published 
elsewhere.14,15 A brief summary of each of the studies is presented below. All three studies were 
approved by Human Subjects Committees. All of the patients signed written informed consent 
prior to enrollment. 
 Symptom Clusters Study. This study was designed to identify symptom clusters and their 
effects on the physical and psychological functioning of patients with metastatic disease. Patients 
were recruited consecutively from two major tertiary referral hospitals in Australia. Eligible 
patients were adults (>18 years of age) who could read, write, and understand English; had no 
cognitive limitations; had a primary cancer of breast, lung, colon/rectum, prostate, upper 
gastrointestinal (GI) tract, or ovaries; were diagnosed with metastatic disease in the past month 
or had clinical evidence of progressive metastatic disease; and had a prognosis between four 
months and two years as determined by their clinician. Questionnaires were completed during a 
20 minute face-to-face interview conducted by trained interviewers. Demographic and clinical 
data were obtained from medical record reviews. 
 FPS Study.  This study evaluated multiple symptoms in patients who underwent 
primary or adjuvant radiation therapy (RT). Patients were recruited from two RT departments 
and were eligible to participate if they: were ≥18 years of age; were scheduled to receive primary 
or adjuvant RT for breast, prostate, lung, or brain cancer; were able to read, write, and 
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understand English; and had a Karnofsky Performance Status (KPS) score of ≥60. Patients were 
excluded if they had: metastatic disease, more than one cancer diagnosis, or a diagnosed sleep 
disorder. Patients completed the study questionnaires at the time of their simulation visit. 
Medical records were reviewed for disease and treatment information. 
Symptom Prevalence Study.  This study used self-report questionnaires to obtain 
information from a convenience sample of oncology outpatients. Patients were recruited from 
four outpatient settings and were eligible to participate if they were >18 years of age; were able 
to read, write, and understand English; had KPS scores of >50; and were receiving active cancer 
treatment. Patients completed the study questionnaires in their home and returned them to the 
research office using a postage paid envelope.  
Instruments 
Demographic and Clinical Characteristics.  Demographic information on age, gender, 
marital status, and living arrangements were obtained at enrollment. Because of differences in 
the educational systems in Australia and the U.S., data on education were recoded into a 
dichotomous variable (i.e., no post high school versus post high school education). In addition, 
patients’ medical records were reviewed for cancer diagnosis, presence of metastatic disease, and 
current treatment regimens (i.e., none, chemotherapy (CTX), RT, or both CTX and RT). 
In the Australian study, patient’s functional status was rated by their clinician using the 
Eastern Cooperative Oncology Group (ECOG) Performance Status score that ranged from 0 
(fully active) to 4 (disabled).16 In the U.S. studies, patients rated their functional status using the 
KPS scale.17 Based on the recommendations of Verger and colleagues,18 the KPS scores were 
converted to ECOG scores for use in subsequent analyses. 
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MSAS.  All three studies used the MSAS to evaluate the occurrence, severity, frequency, 
and distress of 32 symptoms commonly associated with cancer and its treatment.8 The MSAS is 
a self-report questionnaire designed to measure the multidimensional experience of symptoms. 
Using the MSAS, patients were asked to indicate whether or not they had experienced each 
symptom in the past week (i.e., symptom occurrence). If they had experienced the symptom, 
they were asked to rate its frequency of occurrence, severity, and distress.  
From the 32 items on the MSAS, the total number of symptoms reported by each patient 
was calculated. In addition, three subscale scores (i.e., Global Distress Index, physical (MSAS 
PHYS), psychological (MSAS PSYCH)) and a total MSAS score were calculated.8 The 
reliability and validity of the MSAS is well established. Cronbach’s alphas for the physical 
subscale, psychological subscale, Global Distress Index, and total MSAS score were 0.82, 0.77, 
0.83, and 0.87, respectively. 
Multidimensional Quality of Life Scale- Cancer (MQOLS-CA).  In the two U.S. studies, 
the MQOLS-CA was used to evaluate QOL. The MQOLS-CA comprises 33 items that measure 
four dimensions of QOL (i.e., physical well-being, psychological well-being, social well-being, 
spiritual well-being) in cancer patients. Each item is rated on a 0 to 10 scale.19 A total QOL 
score, as well as subscale scores, were calculated, with higher scores indicating a better QOL. 
MQOLS-CA data from the two U.S. studies were combined and the resultant Cronbach’s alpha 
for the MQOLS-CA total score was 0.94. 
Statistical Analysis 
The three data sets were combined and data were analyzed using SPSS version 20. 
Descriptive statistics, means, and standard deviations for quantitative variables and frequencies 
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and percentages for categorical variables were generated to describe various patient 
characteristics. 
LCA was used to identify subgroups of patients (i.e., latent classes) with similar symptom 
experiences.20,21 Whereas the MSAS evaluates the occurrence, frequency, severity, and distress 
associated with 32 symptoms, for this analysis and consistent with previous studies,7,11 the LCA 
was performed based on patients’ ratings of symptom occurrence. 
LCA identifies latent classes based on an observed response pattern.22,23 In order to have 
a sufficient number of patients with each symptom to perform the LCA, the symptoms that 
occurred in >40% of the patients were used to identify the distinct latent classes. A total of 13 of 
32 symptoms from the MSAS occurred in >40% of the patients. 
  The final number of latent classes was identified by evaluating the Bayesian 
Information Criterion (BIC) and entropy. The model that fits the data best has the lowest BIC.24 
In addition, well-fitting models produce entropy values of >0.80.25 Finally, well-fitting models 
“make sense” conceptually and the estimated classes differ as might be expected on variables not 
used in the generation of the model.24 
  The LCA was performed using MplusTM Version 7.26,27 Estimation was carried out with 
robust Maximum-Likelihood (MLR) and the Expectation-Maximization (EM) algorithm.20 The 
LCA was done in two stages. First, the number of latent classes that fit the data best, without 
covariates (i.e., the unconditional model) was identified. Then six covariates that were associated 
with symptom occurrence were evaluated in the LCA (i.e., age; gender; ECOG Performance 
Status in two groups [i.e., high performance (ECOG 0 and 1) versus low performance (ECOG 2, 
3, 4)]; diagnosis in two groups [other versus lung cancer]; radiation treatment [yes/no], CTX 
treatment [yes/no]). Each covariate was evaluated separately, outside the model, for its potential 
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usefulness in improving model fit using the R3STEP procedure.26 Then the covariates that were 
significant predictors of latent class membership were examined within the model. That is, these 
covariates provided information about differences among the latent classes as part of model 
estimation. Initially, as part of this analysis, the complete set of covariates was examined jointly. 
Covariates were removed from the model if they were not significant within the model. The 
Wald Chi-squared statistic was used to evaluate significance at a P-value of <0.05. 
After identifying the latent class solution that best fit the data, differences among the 
latent classes, in demographic and clinical characteristics, MSAS total and subscale scores, and 
QOL outcomes were evaluated using analyses of variance and Chi-square analyses. A P-value of 
<0.05 was considered statistically significant. Post hoc contrasts were done using a Bonferroni 
corrected P-value of 0.008 (0.05/6 pairwise comparisons). 
Results 
Latent Class Analysis 
  A total of 13 symptoms from the MSAS occurred in >40% of the patients (Fig. 1). 
Using LCA, four distinct subgroups of patients were identified based on their ratings of the 
occurrence of these symptoms. Fit indices for the candidate models are shown in Table 1. The 
four-class solution was selected because its BIC was lower than the BIC for both the three- and 
five-class solutions. The four covariates that were included in the final model were: age, ECOG 
Performance Status in two groups (high versus low), diagnosis in two groups (lung cancer versus 
other), and radiation treatment (yes versus no). 
  As summarized in Table 2 and illustrated in Fig. 1, the largest percentage of patients 
(28.0%, n=163) was classified in the “All Low” class. Probability of occurrence for the MSAS 
symptoms for this class ranged from 0.01 to 0.35. The second largest class (26.3%, n=153) was 
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classified as the “Moderate Physical and Lower Psych” class. Probability of occurrence for the 
MSAS symptoms for this class ranged from 0.17 to 0.83. Although these patients reported 
moderate occurrence rates for the majority of the physical symptoms (i.e., lack of energy, pain, 
feeling drowsy, difficulty sleeping, difficulty concentrating, dry mouth, cough, sweats, shortness 
of breath, difficulty with urination), they reported relatively low occurrence rates for the 
psychological symptoms (i.e., worrying (0.19), feeling irritable (0.17), feeling sad (0.17)). The 
third class (25.4%, n=148) was classified as the “Moderate Physical and Higher Psych” class. 
Probability of occurrence for the MSAS symptoms for this class ranged from 0.08 to 0.89. 
However, the probability of occurrence of the psychological symptoms was relatively high (i.e., 
worrying (0.69), feeling irritable (0.52), feeling sad (0.61)). The final class consisted of 20.3% 
(n=118) and was called the “All High” class. Probability of occurrence for the MSAS symptoms 
ranged from 0.46 to 1.0. 
Differences in Patient Characteristics Among the Latent Classes 
  Table 2 summarizes the differences in demographic and clinical characteristics among 
the four latent classes. Compared to the All Low and the Moderate Physical and Lower Psych 
classes, patients in the Moderate Physical and Higher Psych and the All High classes were 
significantly younger. Compared to the All Low class, a higher percentage of patients in the 
other three latent classes were female. A smaller percentage of patients in the Moderate Physical 
and Lower Psych class had completed post high school education compared to the other three 
latent classes. Compared to the All Low and the Moderate Physical and Higher Psych classes, a 
higher percentage of patients in the Moderate Physical and Lower Psych and the All High classes 
had a diagnosis of lung cancer, had metastatic disease, and reported a lower performance status. 
Differences in MSAS Summary Scores Among the Latent Classes 
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  Table 3 summarizes differences among the latent classes in total number of symptoms 
reported (out of 32), as well as differences in MSAS summary scores. In terms of total number of 
symptoms, compared to patients in the other three classes, patients in the All Low class reported 
the lowest number of symptoms. In addition, compared to the Moderate Physical and Lower 
Psych and the Moderate Physical and Higher Psych classes, patients in the All High class 
reported a significantly higher number of symptoms. For the PSYCH subscale score and the 
Global Distress Index, the differences among the four latent classes had the same pattern (i.e., 
All Low < Moderate Physical and Lower Psych < Moderate Physical and Higher Psych < All 
High). For the PHYS subscale score, the differences among the four classes had the following 
pattern: All Low < Moderate Physical and Higher Psych < Moderate Physical and Lower Psych 
< All High. For the MSAS total score, the post hoc contrasts demonstrated the following 
differences among the latent classes: 1) All Low class < Moderate Physical and Lower Psych, 
Moderate Physical and Higher Psych, and All High classes and 2) Moderate Physical and Lower 
Psych and Moderate Physical and Higher Psych classes < All High class. 
Differences in Quality of Life Scores Among the Latent Classes 
  For the two studies conducted in the U.S., differences among the latent classes in 
MQOLS-CA subscale and total scores are summarized in Table 4. Except for the spiritual well-
being scores, the post hoc contrasts demonstrated the following differences among the latent 
classes for the remaining MQOLS-CA subscale scores as well as the total QOL score: 1) All 
Low class > Moderate Physical and Lower Psych, Moderate Physical and Higher Psych, and All 
High classes and 2) Moderate Physical and Lower Psych and Moderate Physical and Higher 
Psych classes > All High class. 
Discussion 
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Rank Order of Symptom Occurrence Among the Latent Classes 
  This study is the first to use LCA and to incorporate clinically meaningful covariates  
into the LCA to identify distinct subgroups of oncology patients based on their reports of the 
occurrence of 13 common symptoms. In this relatively large and heterogeneous sample in terms 
of cancer diagnoses, the percentages of patients were distributed relatively evenly across the four 
latent classes. However, consistent with previous studies,7,12,13 an “All Low” and an “All High” 
symptom subgroup were identified. Of note, patients in the All High class reported an average of 
20 of 32 MSAS symptoms, which is higher than the mean of 10 symptoms reported in a 
systematic review.1 These consistent findings suggest that future studies of symptom burden in 
oncology patients need to employ more sophisticated statistical approaches to identify higher risk 
patients. The reliance on mean number of symptoms will over- and underestimate symptom 
burden and not allow for the identification of patients who warrant more intensive symptom 
management. 
  This study is the first to identify two subgroups of oncology patients who reported 
moderate levels of physical symptoms but differentiated on the occurrence of three psychological 
symptoms (i.e., worrying, feeling irritable, feeling sad). As shown in Table 5, for patients in the 
Moderate Physical and Higher Psych class, worrying (0.69), feeling sad (0.61), and feeling 
irritable (0.52) were among the top eight symptoms. In contrast, in the Moderate Physical and 
Lower Psych class, worrying (0.19), feeling sad (0.17), and feeling irritable (0.17) were the three 
symptoms with the lowest probability of occurrence. Compared to patients in the Moderate 
Physical and Higher Psych class, patients in the Moderate Physical and Lower Psych class were 
older; less likely to have a post high school education; more likely to have a diagnosis of lung 
cancer; more likely to have metastatic disease, and more likely to have a lower performance 
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status. The higher number of lung cancer patients in the Moderate Physical and Lower Psych 
group most likely accounts for the relatively high occurrence rates reported for cough (0.67), dry 
mouth (0.63), and shortness of breath (0.67). No studies were found that identified distinct 
subgroups of oncology patients based on the occurrence of symptoms associated with 
psychological distress. However, in population-based studies of depression28-30 and anxiety,28-30 
older patients tend to report lower occurrence rates for both symptoms.  
  As illustrated in Fig. 1 and Table 5, across all four classes, lack of energy was the most 
common symptom. While the probability of its occurrence for the total sample was 0.75, values 
ranged from 0.35 to 1.00. In addition, pain and feeling drowsy occurred in the top five symptoms 
across all four latent classes. Given their relatively high occurrence rates, clinicians need to 
assess and treat patients for these three symptoms on a routine basis. 
  When the rank order of symptom occurrence is compared between the All High and the 
Moderate Physical and Higher Psych classes, feeling sad (0.96), worrying (0.93), and feeling 
irritable (0.91) were among the top six symptoms in both classes. Additional demographic, 
clinical, and treatment characteristics that contribute to the high occurrence rates for 
psychological distress in both of these classes compared to the other two latent classes warrant 
investigation in future studies. 
Characteristics Associated with a Higher Symptom Burden 
  An important component of this type of research is the identification of demographic, 
clinical, and treatment characteristics that are associated with a higher symptom burden. In this 
study, four salient characteristics were included in the LCA and provided information about 
differences among the latent classes as part of the model estimation. For example, compared to 
the All Low class, patients in the All High class were almost a decade younger. The association 
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between younger age and higher symptom burden is consistent with previous reports.5,7,14,15 
These age-related differences may be related to younger patients receiving more aggressive 
treatments;31,32 age-related changes in the hypothalamic-adrenal-pituitary axis that may mediate 
the occurrence of symptoms;33 or a “response shift” in older patients’ perceptions of 
symptoms.34,35 
  Consistent with previous LCA studies,3,5,7 compared to the All Low class, a higher 
percentage of women were in the other three latent classes. Additional research is warranted on 
gender differences in the occurrence and severity of symptoms in oncology patients because 
findings from primarily cross-sectional studies on gender differences are inconsistent.36-40 
  While a poorer performance status was associated with membership in the All High 
subgroup in previous studies,3,7,10,11 in the current study it was associated with membership in 
both the All High and the Moderate Physical and Lower Psych classes. Almost half of the 
patients in these two subgroups had ECOG scores of between 2 and 4. Although this repeated 
association between higher symptom burden and poorer performance status does not demonstrate 
causality, it suggests that clinicians can use KPS or ECOG scores to identify patients who may 
require more aggressive symptom management. 
  However, the reason why a higher percentage of patients in the Moderate Physical and 
Higher Psych class had better ECOG performance scores than patients in the Moderate Physical 
and Lower Psych class warrants additional investigation. Based on previously published 
associations between poorer performance and higher symptom burden,3,7,10,11 this finding seems 
somewhat contradictory. One potential explanation may be that younger patients with a better 
performance status find their physical symptoms more distressing, which is associated with 
worrying, as well as feelings of irritability and sadness. An alternative explanation is that a 
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higher percentage of patients in the Moderate Physical and Lower Psych class had a diagnosis of 
lung cancer, which is a cancer diagnosis that is often associated with a poorer performance 
status. Because of the limited number of demographic, clinical, and treatment characteristics that 
were available across the three datasets, additional explanations for these subgroup differences 
are not readily apparent. Additional research is warranted to confirm these two subgroups and 
identify additional characteristics that distinguish between the subgroups. 
  Conflicting information exists on whether or not the presence of metastatic disease is 
associated with membership in the All High class, with some studies showing no2,6,7 and others 
showing a positive10,12 association. Given the differences among the latent classes in the current 
study in both the presence of metastasis and performance status scores, additional research is 
warranted to determine how one or both of these characteristics influence symptom burden in 
oncology patients. 
Differences in MSAS Subscale and Total Scores 
  While only 13 of the 32 symptoms on the MSAS were used in the LCA, statistically 
significant, as well as clinically meaningful differences (i.e., range of d = 0.52 to 2.25, where d 
equals the difference between the two groups in standard deviation units) were found among the 
latent classes in the MSAS subscale and total scores (Table 3). Of note, the MSAS PSYCH, 
MSAS PHYS, and MSAS Global Distress Index scores differentiated among the four latent 
classes. However, no differences in total number of MSAS symptoms (out of 32) and MSAS 
Total score were found between the Moderate Physical and Lower Psych and the Moderate 
Physical and Higher Psych classes. Again, this finding suggests that other demographic, clinical 
and treatment characteristics need to be evaluated to be able to differentiate these two latent 
classes. 
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  Consistent with our previous reports,2,6,7 patients in the All High class reported worse 
QOL outcomes compared to the other three symptom subgroups. Compared to the All Low class, 
the differences in QOL subscale and total scores for the other three latent classes represent not 
only statistically significant but clinically meaningful decrements in QOL (i.e., range of d=1.38 
to d=1.64).41,42 These findings demonstrate the differential effect of symptom burden on patients’ 
QOL. 
Strengths and Limitations 
 Several study strengths and limitations need to be acknowledged. The large sample size 
allowed for the inclusion of clinically relevant covariates within the LCA to identify distinct 
symptom subgroups. In addition, the heterogeneous cancer diagnoses, stages of disease, and 
current treatments make the findings generalizable to the majority of oncology practices. 
Because three data sets were combined, the analyses were limited to those characteristics that 
were collected across all three studies. The evaluation for differences in QOL scores among the 
symptom subgroups was limited to the two U.S. studies. Finally, future studies need to evaluate 
the impact of medications on symptom subgroup membership. 
  Despite these limitations, this study provides important information on subgroups of 
oncology patients with distinct symptom experiences. If the specific latent classes identified in 
this study are replicated in future studies, the phenotypic characteristics that differentiate among 
these classes may be useful in the development of symptom management interventions for higher 
risk patients. Future studies can evaluate for molecular characteristics that distinguish among the 
patient subgroups. These types of studies would provide insights into the mechanisms that 
underlie multiple co-occurring symptoms in oncology patients. 
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Figure Lgend 
Fig. 1.  Probability of symptom occurrence for the total sample (i.e., total sample proportion) and 
each of the latent classes for the 13 symptoms on the Memorial Symptom Assessment Scale that 
occurred in >40% of the total sample (n=582). 
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Table 1 - Latent Class Fit Indices for Two- Through Five-Class Solutions  
 
 Unconditional Model Model with Covariates 
 
Model LL BIC Entropy LL BIC Entropy 
     
 
2 Class  -4590.08 9352.65 .80   -4454.23 9105.81 .80 
 
3 Class  -4469.58 9201.09 .78   -4325.71 8963.38 .79 
 
4 Classa  -4400.73  9152.83 .77   -4230.63 8887.82 .78 
 
5 Class  -4361.80 9164.40 .80   -4176.03 8893.21 .80 
 
 
a
 The four-class solution was selected because the BIC was lower than in both the 3- and 5-
class solutions. This difference was consistent when including four covariates in the model. 
 
Abbreviations:  BIC= Bayesian Information Criterion; LL = log-likelihood 
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Table 2 - Differences in demographic and clinical characteristics among the four latent classes 
 
 
Characteristic All Low (1) 
 
 
n = 163 
(28.0%) 
Moderate 
Physical and 
Lower Psych (2) 
n = 153 
(26.3%) 
Moderate Physical 
and Higher Psych 
(3) 
n = 148 
(25.4%) 
All High (4) 
 
 
n = 118 
(20.3%) 
Statistics 
Age in years (mean + SD) 66.0 (10.3) 64.3 (10.5) 56.3 (11.9) 56.7 (12.7) F(3,578)=29.11 
p<.0001 
1 and 2 > 3 and 4 
Age range (years) 29 to 86 35 to 86 24 to 83 20 to 84  
 % % % %  
Female* 37.4 58.2 60.1 68.6 Χ2 = 31.42 
p<.0001 
1 < 2, 3, and 4 
Lives alone 22.5 28.5 24.3 29.7 NS 
Married/partnered 69.8 55.9 61.0 55.6 Χ2 = 8.32 
p=.040 
No significant 
contrasts 
Education – Post high school* 65.8 45.0 69.2 65.8 Χ2 = 22.93 
p<.0001 
2 < 1, 3, and 4 
Diagnosis 
 
 Breast 
 Prostate 
 
 Lung 
 Other 
 
 
23.9 
47.9 
 
5.5 
22.7 
 
 
32.0 
12.4 
 
30.1 
25.5 
 
 
45.3 
25.7 
 
1.4 
27.7 
 
 
35.6 
12.7 
 
16.9 
34.7 
Χ
2
 = 120.92 
p<.0001 
3>1 
1 > 2, 3, and 4 
3 > 2 and 4 
2 and 4 > 1 and 3 
NS 
Lung versus other 
 Lung cancer* 
 Other cancer 
 
5.5 
94.5 
 
30.1 
69.9 
 
1.4 
98.6 
 
16.9 
83.1 
Χ
2
 = 65.83 
p<.0001 
1 and 3 < 2 and 4 
Metastasis* 22.8 46.4 25.7 47.5 Χ2 = 33.07 
p<.0001 
1 and 3 < 2 and 4 
Treatment 
  
 None 
 
 
7.4 
 
 
28.1 
 
 
12.8 
 
 
15.3 
Χ
2
 = 57.56 
p<.0001 
2 > 1 and 3 
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 Only radiation 
 Only chemotherapy 
 Both 
61.3 
20.2 
11.0 
35.9 
28.8 
7.2 
42.6 
26.4 
18.2 
30.5 
35.6 
18.6 
1 > 2, 3, and 4 
4 > 1 
3 and 4 > 2 
ECOG Performance Status 
 Higher performance (ECOG 0 and 1)* 
 Lower performance (ECOG 2, 3, 4) 
 
87.1 
12.9 
 
52.9 
47.1 
 
86.5 
13.5 
 
49.2 
50.8 
Χ
2
 = 87.96 
p<.0001 
1 and 3 > 2 and 4 
*Reference group 
 
Abbreviations: ECOG = Eastern Coopertive Oncology Group; SD = standard deviation 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 3 - Differences in Memorial Symptom Assessment Scale (MSAS) summary scores among the four latent classes 
 
MSAS scores All Low (1) 
 
 
n = 163 
(28.0%) 
Moderate 
Physical and 
Lower Psych (2) 
n = 153 
(26.3%) 
Moderate 
Physical and 
Higher Psych (3) 
n = 148 
(25.4%) 
All High (4) 
 
 
n = 118 
(20.3%) 
Statistics 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Total number of symptoms 3.88 (2.41) 10.72 (3.87) 10.74 (3.56) 20.26 (5.24) F(3,578)=427.54 
p<.0001 
1 < 2, 3, and 4 
2 and 3 < 4 
MSAS PSYCH Subscale score 0.17 (0.23) 0.58 (0.46) 1.17 (0.61) 1.89 (0.59) F(3,578)=327.211 
p<.0001 
1 < 2 < 3 <4 
MSAS PHYSICAL Subscale score 0.25 (0.27) 0.90 (0.53) 0.75 (0.45) 1.48 (0.51) F(3,578)=176.08 
p<.0001 
1 <3 <2 <4 
MSAS Global Distress Index 0.25 (0.26) 0.85 (0.54) 1.11 (0.51) 1.91 (0.50) F(3,578)=302.14 
p<.0001 
1 <2 <3 <4 
MSAS Total score 0.22 (0.15) 0.71 (0.34) 0.70 (0.28) 1.35 (0.39) F(3,578)=328.85 
p<.0001 
1 < 2, 3, and 4 
2 and 3 < 4 
 
Abbreviation: SD = standard deviation 
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Table 4 - Differences in Multidimensional Quality of Life Scale-Cancer (MQOLS-CA) subscale and total scores among the four latent 
classes* 
 
MQOLS scores All Low (1) 
 
 
n = 119 
(33.8%) 
Moderate 
Physical and 
Lower Psych (2) 
n = 56 
(15.9%) 
Moderate 
Physical and 
Higher Psych (3) 
n = 99 
(28.1%) 
All High (4) 
 
 
n = 78 
(22.2%) 
Statistics 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Physical well-being score 8.35 (1.35) 6.59 (1.74) 7.09 (1.48) 5.58 (1.58) F(3,348)=56.02 
p<.0001 
1 > 2, 3, and 4 
2 and 3 > 4 
Psychological well-being score 7.65 (1.49) 6.08 (1.79) 5.66 (1.71) 4.43 (1.65) F(3,346)=64.17 
p<.0001 
1 > 2, 3, and 4 
2 and 3 > 4 
Social well-being score 7.76 (1.67) 6.25 (2.13) 5.79 (2.07) 4.69 (1.90) F(3,347)=43.10 
p<.0001 
1 > 2, 3, and 4 
2 and 3 > 4 
Spiritual well-being score 5.31 (1.84) 5.87 (2.17) 5.26 (2.19) 5.06 (2.21) F(3,348)=1.76 
p=.155 
Total quality of life score 7.41 (1.19) 6.16 (1.37) 5.90 (1.34) 4.79 (1.21) F(3,342)=67.96 
p<.0001 
1 > 2, 3, and 4 
2 and 3 > 4 
 
*Data from the two Unites States’ studies 
 
Abbreviation: SD = standard deviation 
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Table 5 – Rank order of the probability (P) of occurrence of the symptoms for the total sample and the four latent classes 
 
 
Rank Total Sample P All Low P Moderate 
Physical/Lower Psych 
P Moderate 
Physical/Higher 
Psych 
P All High P 
1 Lack of energy .749 Lack of energy .351 Lack of energy .834 Lack of energy .894 Lack of energy 1.00 
2 Pain .644 Pain .337 Pain .736 Worrying .692 Feeling sad .969 
3 Feeling drowsy .591 Problems with 
urination 
.299 Feeling drowsy .675 Pain .661 Feeling drowsy .931 
4 Difficulty sleeping .536 Difficulty sleeping .223 SOB .673 Difficulty sleeping .661 Worrying .926 
5 Difficulty 
concentrating 
.460 Feeling drowsy .216 Cough .668 Feeling drowsy .642 Pain .924 
6 Worrying .436 Sweats .165 Dry mouth .625 Feeling sad .613 Feeling irritable .909 
7 Dry mouth .428 Feeling irritable .147 Difficulty sleeping .525 Difficulty 
concentrating 
.574 Difficulty 
concentrating 
.878 
8 Feeling irritable .404 Dry mouth .122 Difficulty concentrating .445 Feeling irritable .522 Difficulty 
sleeping 
.821 
9 Feeling sad .402 Cough .091 Sweats .324 Sweats .427 Dry mouth .809 
10 Cough .378 Worrying .081 Problems with 
urination 
.200 Dry mouth .252 Cough .673 
11 Sweats .371 Difficulty 
concentrating 
.066 Worrying .189 Problems with 
urination 
.239 SOB .671 
12 SOB .345 SOB .036 Feeling irritable .174 Cough .153 Sweats .645 
13 Problems with 
urination 
.290 Feeling sad .014 Feeling sad .173 SOB .081 Problems with 
urination 
.462 
 
Abbreviation: SOB = shortness of breath 
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